Stream Link 1 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1676851&tp_key=3ac8b0837b
Stream Link 8 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1676852&tp_key=fc3a24da52
This activity is part 2 of a 3-part webinar curriculum and includes a Powered by Patients™ video interview.
Program Description
Anti-vascular endothelial growth factor (anti-VEGF) agents act as inhibitors to the growth of new blood vessels, which can translate to potentially improved visual outcomes and slowed disease progression in ophthalmologic conditions, including age-related macular degeneration (AMD) and diabetic macular edema (DME). There are complexities that differentiate this class from other recently advanced ophthalmologic therapies. While effective, frequent anti-VEGF injections can be burdensome for patients, leading to potential nonadherence and impacting treatment success. This webinar explores strategies for specialty pharmacists to support the ophthalmology team in optimizing anti-VEGF therapy for patients with AMD and DME. The discussion will delve into the mechanisms of action of approved anti-VEGF agents, analyzing real-world data on their safety and efficacy in both conditions, as well as current guideline-recommended dosing approaches to individualize treatment plans. A Powered by Patients™ interview will be included within the presentation, featuring the perspective of an individual living with AMD/DME and their experience with anti-VEGF injections.
Target audience: Specialty pharmacists
Type of activity: Application
Release date: August 8, 2024
Expiration date: October 8, 2024
Time to complete activity: 1.0 hour
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the mechanisms of action of available anti-vascular endothelial growth factor (VEGF) agents for age-related macular degeneration (AMD) and diabetic macular edema (DME) based on real-world safety and efficacy data
- Compare the current guideline recommendations for anti-VEGF dosing strategies in the treatment of AMD
- Explore patient-specific treatment plans that incorporate individualized anti-VEGF therapy selection in DME
- Identify the potential ocular and systemic adverse effects associated with anti-VEGF therapy in AMD and DME and strategies for their identification, prevention, and management
W. Lloyd Clark, MD
Assistant Clinical Professor of Ophthalmology
University of South Carolina School of Medicine
Retina Specialist
Palmetto Retina Center
Columbia, South Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-24-181-L01-P. The activity is available for CE credit through October 8, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
W. Lloyd Clark, MD, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Regeneron, Genentech, Bayer, Kodiak Sciences Inc, Outlook Therapeutics, Inc, Oculis
Consultant: Regeneron, Genentech, Ocula Therapeutics, Amgen, Cardinal Health, EyePoint Pharmaceuticals, Inc, Notal Vision, Inc
Speakers Bureau: Genentech, Regeneron
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms